HDO Health Company Profile

Background

Overview

HDO Health is a veteran-led medical device company founded in 2021, dedicated to developing innovative technologies aimed at preventing deaths from uncontrolled bleeding, particularly from traumatic junctional wounds. The company's mission is to design and bring to market life-saving, cost-effective medical devices. Their primary focus is on emergency medicine, trauma, and combat care markets.

Mission and Vision

Mission: To develop and bring to the world innovative, life-saving, cost-effective medical devices.

Vision: To build a team and company united by a noble mission and guided by common values that helps save lives.

Values

Heart Led: Embracing servant leadership principles, supporting military, first responders, and others who serve above self.

Data Driven: Delivering products and services supported by substantive research, evidence, and data.

Outcome Focused: Ensuring products work as designed, every single time, to solve complex unmet healthcare needs.

Key Strategic Focus

Core Objectives

HDO Health aims to leverage innovation ecosystems and partnerships to design, develop, and commercialize life-saving and world-changing products.

Areas of Specialization

The company specializes in medical devices designed to control hemorrhaging, particularly in junctional areas where traditional tourniquets are less effective.

Key Technologies Utilized

HDO Health's flagship product, the Journiquet™, is an advanced tourniquet designed to effectively stop bleeding in areas where traditional tourniquets are less effective. It is simple, fast, light, and secure, requiring only gross motor movements for application. The device is pre-assembled, compact, and lightweight, crafted from durable components to withstand harsh field conditions.

Primary Markets Targeted

The primary markets targeted include emergency medicine, trauma care, combat care, military personnel, first responders, and healthcare providers.

Financials and Funding

Funding History

HDO Health has participated in several entrepreneurship programs, accelerators, and startup studios, including Rev1 Ventures, the National Security Innovation Network, Bunker Labs, and Warrior Rising. The company has secured nearly $500K in non-dilutive funding. They have achieved a Technology & Manufacturing Readiness Level (TRL) of 6, received Class II 510(k) pre-submission feedback, and have intellectual property with patents and trademarks pending.

Recent Funding Rounds

In November 2023, HDO Health received a grant of $1,000 from Founders First CDC.

Notable Investors

Investors include Founders First CDC and the Ohio Department of Development.

Utilization of Capital

The capital is intended to support the commercialization of the Journiquet™, including regulatory approvals, manufacturing, distribution, and further product development.

Pipeline Development

Key Pipeline Candidates

The primary product in development is the Journiquet™, a novel, class II, non-sterile, non-invasive, single-use medical device designed to stop traumatic junctional bleeding. The device is pending submission for 510(k) clearance by the U.S. Food and Drug Administration and is not currently available for sale within the United States.

Stages of Development

The Journiquet™ is in the pre-commercialization stage, with pending regulatory submissions and ongoing product development.

Target Conditions

The device targets uncontrolled bleeding from traumatic junctional wounds, particularly at the torso-appendage junctions.

Anticipated Milestones

Anticipated milestones include obtaining 510(k) clearance from the FDA, initiating manufacturing, and launching the product in the U.S. market.

Technological Platform and Innovation

Proprietary Technologies

The Journiquet™ is a proprietary device designed to effectively control bleeding in areas where traditional tourniquets are less effective. Its design emphasizes ease of use, requiring only gross motor movements for application, and is crafted from durable components to withstand harsh field conditions.

Significant Scientific Methods

The development of the Journiquet™ involved extensive input from warfighters and first responders, ensuring the device meets the practical needs of its end-users. The design process emphasized simplicity, speed, and security, integrating easily into existing training and supply chains.

Leadership Team

Executive Profiles

Bryan J. Stewart: Founder and Chief Executive Officer. Former USMC Infantry Officer with over 25 years in healthcare, including roles at Medtronic, Biomet, AmeriPath (Quest), and Ventana Medical Systems (Roche).

Tanya Nocera, Ph.D.: Co-founder and Vice President of Research and Development. Co-Inventor and Professor of Practice & Director of Undergraduate Education in Biomedical Engineering at Ohio State University.

J. Allen McElroy, M.D.: Co-founder and Vice President of Medical Affairs. General & Trauma Surgeon, Assistant Professor of Surgery at West Virginia University, SWAT Medic, and Tactical Medicine Trainer.

Nadi Graham: Co-founder and Vice President of Education and Training. Over 20 years on the Special Response Team of the Ohio State Highway Patrol, SWAT Medic, and Tactical Medicine Trainer.

Competitor Profile

Market Insights and Dynamics

The market for hemorrhage control devices is growing, driven by the need for effective solutions in emergency medicine, trauma care, and combat situations. Uncontrolled bleeding remains a leading cause of preventable deaths worldwide, highlighting the demand for innovative medical devices.

Competitor Analysis

Key competitors in the hemorrhage control device market include:

RevMedx: Specializes in trauma care, hemorrhage control, and battlefield medicines.

Beeken Biomedical: Focuses on medical devices for hemorrhage control.

LifeScience PLUS, Inc.: Develops medical devices for trauma care and hemorrhage control.

Strategic Collaborations and Partnerships

HDO Health has collaborated with the Ohio State Innovation Foundation to commercialize the Journiquet™ technology, leveraging academic research and innovation.

Operational Insights

HDO Health differentiates itself through its veteran-led team, commitment to servant leadership, and focus on data-driven, outcome-focused product development. The company's emphasis on simplicity and ease of use in its products positions it uniquely in the market.

Strategic Opportunities and Future Directions

HDO Health plans to expand its product line to address other critical unmet needs in emergency medicine and trauma care. The company's strong foundation in innovation and partnerships provides a solid platform for future growth and impact.